ATOSSA THERAPEUTICS, INC. Stock Split Ratio
ATOSSA THERAPEUTICS, INC. (ATOS) had Stock Split Ratio of 6.70% as of 2026-02-02, per its 10-Q filed 2026-08-07.
Financial Statements › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-07
- 2026-02-02: Stockholders' Equity Note, Stock Split, Conversion Ratio 6.70%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2026-02-02 | 6.70% 10-Q · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |